Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Medical Laboratory Technology Journal Tropical Health and Medical Research Journal
Cengiz Bayram
Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey
Religion Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Platelet/Monocyte Ratio Before Treatment Predicts Prognosis in Solid Childhood Cancers Özlem Terzi; Cengiz Bayram; Ali Ayçiçek; Ezgi Uysalol; Cennet Nur Baş; Hüseyin Avni Solgun; Tuba Tahtakesen; Esra Arslantaş; Sibel Tekgündüz
Medical Laboratory Technology Journal Vol. 8 No. 2 (2022): December
Publisher : Poltekkes Kemenkes Banjarmasin Jurusan Analis Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (399.893 KB) | DOI: 10.31964/mltj.v8i1.482

Abstract

The prognostic value of thrombocytosis and inflammatory biomarkers in adult cancer patients has been the subject of many studies. This study investigated the role of platelet count and other inflammatory biomarkers in the prognosis of solid childhood tumours. The data of 176 pediatric patients diagnosed with solid tumours were evaluated retrospectively; 150 patients still under follow-up were included in the study. We examined the relationship between platelet count, platelet/neutrophil ratio (PNR), platelet/lymphocyte ratio (PLR) and platelet/monocyte ratio (PMR) at the time of diagnosis on survival. The mean age of diagnosis was 7.91 ± 5.75 years, and 60.7% were male. The mean platelet count of the patients was 424.326 ± 167197.32. The median (range) follow-up was 13 (1-68) months. Relapse was seen in 18% of the patients, and 9.3% died. The relationship between PMR and overall survival (OS) and event-free survival times (EFS) was statistically significant (p=0.002 and p=0.016, respectively). However, no statistically significant association was found for PLR or PNR. Overall survival and EFS were significantly poorer in this cohort in patients with high pretreatment PMR.
The Covid-19 Disease in Pediatric Cancer Patients: A Single Center Experience Özlem Terzi; Hüseyin Avni Solgun; Nuran Karabulut; Sibel Tekgündüz; Fatma Sek; Cengiz Bayram; Ali Ayçiçek
Tropical Health and Medical Research Vol. 4 No. 2 (2022): Tropical Health and Medical Research
Publisher : Baiman Bauntung Batuah Center

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35916/thmr.v4i2.73

Abstract

Children with cancer can have a severe disease when infected with respiratory viruses. In this study, we aimed to understand the clinical course and outcomes of SARS-CoV-2 infection in children with cancer. Data evaluated about laboratory-confirmed SARS-CoV-2 infections in sixty-three children (<18 years) with cancer between 01.06.2020 - 01.08.2021 were retrospectively reviewed. Data for demographics, oncological diagnosis, clinical course, and cancer therapy details were collected. Primary outcomes were disease severity and modification to cancer-directed therapy. The median (range) age was 7.6 ± 5.3 (0-18) years, and the most common underlying diagnosis was leukemia (74.6%). The most common symptom was fever (67.7%), and most patients had symptoms (70%). The mild disease was most common (60.3%). During Covid-19 infection, disease severity increased 23 times (p=0.003) in those with fever and 4.083 (p=0.045) in those with neutropenia. It was observed that the severity of the disease increased 2.589 times as CRP increased (p<0.001). However, few patients (9.5%) were admitted to the intensive care unit. Five patients died, but none of the deaths could be attributed to Covid-19 alone. Most patients did not experience chemotherapy treatment interruption (57%). When interruption did occur, this duration was 13.9±14.3 (1.0-60.0) days. In this cohort of pediatric oncology patients, nearly 43% of patients who had Covid-19 were their chemotherapy interrupted. Future studies will only reveal the final effect of the pandemic on childhood cancer.
Co-Authors Ali Ayçiçek Ali Ayçiçek Cennet Nur Baş Esra Arslantaş Ezgi Uysalol Fatma Sek Hüseyin Avni Solgun Hüseyin Avni Solgun Nuran Karabulut Özlem Terzi Özlem Terzi Sibel Tekgündüz Sibel Tekgündüz Tuba Tahtakesen